Drug Trial Radar · NCT03588299
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Nov 7, 2018
Primary completion
Sep 15, 2026
Study completion Sep 15, 2026
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Ultragenix pharmaceutical
- First posted
- Jul 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a healthy copy the human body may produce clotting factor on its own. Hemophilia A is a bleeding disorder in which the human body does not have enough clotting factor VIII, a protein that controls bleeding. Researcher want to find the optimal dose of BAY 2599023 (DTX201) so that the body may produce enough clotting factor on its own.
Conditions
- Hemophilia A
Interventions
BAY2599023 (DTX201)Drug
Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with adverse events (AEs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and AEs/SAEs of special interestTime frame: Up to 5 years.
Locations
13 sites in 6 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital - Hematology / Oncology
Little Rock, Arkansas
C.S. Mott Children's Hospital - Hematology / Oncology
Ann Arbor, Michigan
UW Health Carbone Cancer Center
Madison, Wisconsin
SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD
Sofia, Sofia City Province, Bulgaria
CHU Rennes - Hopital Pontchaillou
Rennes, Brittany Region, France
APHP-Hopital Necker Enfants malades
Paris, Île-de-France Region, France
Universitätsklinikum des Saarlandes
Homburg, Saarland, Germany
Vivantes Klinikum im Friedrichshain
Berlin, State of Berlin, Germany
Academisch Medisch Centrum (AMC)
Amsterdam, North Holland, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Provincie Groningen, Netherlands
Erasmus Medisch Centrum
Rotterdam, South Holland, Netherlands
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands
Manchester Royal Infirmary | Haematology
Manchester, Greater Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.